+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction



Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction



Haemophilia 22(2): 240-247



Inhibitor formation complicates haemophilia treatment and requires immune tolerance induction to rid inhibitors over 5 BU. In the prospective, randomized International Immune Tolerance Study, immune tolerance induction was equally effective with high-dose (HD) (200 IU kg-1 day-1 ) and low-dose (LD) (50 IU kg-1 3× per week) factor VIII, but haemorrhages were twofold higher in the LD arm. This finding was unexpected as inhibitors neutralize FVIII activity. We hypothesized that the thrombin generation assay (TGA), a global measure of clot formation, might predict bleeding better than FVIII levels. We evaluated TGA using relipidated tissue factor (TF) on 83 thawed, recalcified corn trypsin inhibitor/citrate plasma samples from 31 subjects (17 HD, 14 LD) who participated on the ITI study, and who had sufficient sample available and appropriate informed consent. There were no significant differences in peak thrombin, estimated thrombin potential, maximum rate or lag time between HD and LD arms; between pre-, during and post-ITI time points, or after FVIII spiking. In 19 subjects (12 HD, 7 LD) with anti-FVIII<1.0 BU, the prevalence of non-neutralizing antibody (NNA) and neutralizing antibody (NA) was 89.5% (17/19), and the latter strongly correlated with anti-VIII titer, r = 0.73 [95% CI: 0.55, 0.88]. In haemophilia inhibitor patients, thrombin generation is present, but does not predict bleeding risk. Following tolerance induction, NNA remains detectable in the majority.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 059130541

Download citation: RISBibTeXText

PMID: 26517283

DOI: 10.1111/hae.12830


Related references

First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study. Haemophilia 22(1): 87-95, 2016

Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay. Haemophilia 23(5): 769-776, 2017

Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia 15(3): 718-726, 2009

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. Haemophilia 23(5): 654-659, 2017

The Japanese Immune Tolerance Induction (J-ITI) study in haemophilia patients with inhibitor: Outcomes and successful predictors of ITI treatment. Haemophilia 24(5): E328-E337, 2018

Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sanguinis 77(Suppl. 1): 49-54, 1999

Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and Outcome. Vox Sanguinis 77(Suppl. 1): 49-54, 1999

The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. Haemophilia 22(4): E286-E291, 2016

Thrombin generation in patients with acquired haemophilia and clinical bleeding risk. British Journal of Haematology 153(1): 136-139, 2011

Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series. Haemophilia 16(1): 90, 2010

Successful induction of immune tolerance in a patient with haemophilia B with inhibitor. Haemophilia 9(3): 340-342, 2003

A novel approach to immune tolerance induction in haemophilia A with factor VIII inhibitor. Haemophilia 25(1): E48-E50, 2019

Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 14(1): 44-49, 2008

Successful induction of immune tolerance with FIX recombinant in a patient with haemophilia B with inhibitor. Haemophilia 10(4): 401-404, 2004

Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction. Haemophilia 18(4): E349-E351, 2012